BioSpace News Archive

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the CONNECT-FX ( C linical study O f Ca NN abidiol (CBD) in Childr E n and Adoles C en T s with F ragile X ) trial describing the role of FMR1 methylation status in children and adolescents with Fragile X syndrome (FXS) as

Venus Concept Inc., a global medical aesthetic technology leader, announced that third quarter of fiscal year 2020 financial results will be released before the market opens on Monday, November 16, 2020.

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced preliminary third quarter 2020 revenue and provided a business update.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via webcast on Monday, November 9, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:45 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Nov

DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2020 , at 5:00 p.m. Eastern Time . The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web pa

Tarsus Pharmaceuticals, Inc. announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $88.0 million, before underwriting discounts, commissions, and offering expenses payable by Tarsus.